Liver neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
TP53 mutations in metastatic liver tumors and corresponding primary tumors were identical in 96.9% (31/32), including some patients with heterogeneous primary tumor components.
|
30703342 |
2019 |
Liver neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
The mRNA expression levels of PTEN and p53 in normal liver, tumor-adjacent and liver tumor samples were detected via RT-PCR.
|
28952211 |
2019 |
Liver neoplasms
|
0.700 |
Biomarker
|
group |
RGD |
Effect of human umbilical cord blood derived CD34+ hematopoietic stem cell on the expression of Wnt4 and P53 genes in a rat model of hepatocellular carcinoma.
|
29429512 |
2018 |
Liver neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
Here we demonstrated that the utility of this approach resulted in macroscopic liver tumors as early as 4 months' post injection and most tumors harbored both p53 and Pten loss-of-function alterations.
|
28584302 |
2017 |
Liver neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
However, we observed that SOCS1-deficient mice developed numerous and large liver tumor nodules following treatment with the hepatocarcinogen diethylnitrosamine (DEN) without showing increased interleukin-6 production or activation of p53.
|
26725321 |
2016 |
Liver neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
Therefore, we hypothesize that a recombinant NDV expressing P53 would be an ideal agent for the hepatoma therapy.
|
27465066 |
2016 |
Liver neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
An inverse correlation existed between miR-1228 and p53 expression in hepatoma tissues compared with the adjacent tissues and three hepatoma cell lines.
|
25422913 |
2015 |
Liver neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
Tumorigenesis studies using an established liver tumor cell line confirmed a positive role of autophagy in tumorigenesis and a negative role of p53 in this process when autophagy was impaired.
|
25526090 |
2015 |
Liver neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
In addition, α-PA up-regulated nuclear p53 and down-regulated cytoplasmic p53 expression in J5 cells.
|
25649747 |
2015 |
Liver neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
Connexin32 regulates hepatoma cell metastasis and proliferation via the p53 and Akt pathways.
|
25426556 |
2015 |
Liver neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Knockdown of WWP1 inhibits growth and induces apoptosis in hepatoma carcinoma cells through the activation of caspase3 and p53.
|
24792179 |
2014 |
Liver neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
This compound binds to and abolishes the p53 protein, producing a genomic instability that promotes both the neoplastic progression and the hepatoma reprogramming.
|
23287475 |
2013 |
Liver neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
The effects of both compounds on cell invasion are dependent on p53 and imply that α-dicarbonyls could be efficacious in the treatment of p53-expressing invasive liver tumors.
|
24071451 |
2013 |
Liver neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
We investigated the role of XPD in cell apoptosis of hepatoma and its relationship with p53 during the regulation of hepatoma bio-behavior.
|
21264535 |
2012 |
Liver neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
Targeted stimulation of the caspase-8 promoter by interferons alpha and gamma, cytotoxic drugs or p53 can substantially sensitize hepatoma cells for apoptosis, whereas hepatocellular carcinoma frequently present an inactive caspase-8 gene promoter.
|
22153863 |
2012 |
Liver neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
Following dosage and ratio optimization, polypolex formed by surface modified nHAP and p53 expressing plasmid was applied in vitro for human hepatoma HePG2 cell, and then in vivo for rabbit hepatic VX2 tumour by injection of polypolex/lipodoil emulsion to the hepatic artery in a tumour-target manner.
|
22340582 |
2012 |
Liver neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
An iodized oil emulsion was used as a p53 vector for intra-arterial gene delivery to treat hepatic tumors.
|
22441128 |
2012 |
Liver neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Using short hairpin RNA against p53, transient ectopic expression of wild-type p53 or mutant p53 (R248W or R175H), and a p53- and p21-dependent luciferase reporter assay, we demonstrated that growth arrest and apoptosis of FaDu (human pharyngeal squamous cell carcinoma), Hep3B (hepatoma), and MG-63 (osteosarcoma) cells induced by aloe-emodin (AE) are p53-independent.
|
21308745 |
2011 |
Liver neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
Carcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation.
|
21563203 |
2011 |
Liver neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
Here we have shown that the LIM domain protein Enigma directly interacts with MDM2 to form a ternary complex with p53 in vitro and in human hepatoma and colon carcinoma cell lines and mouse embryonic fibroblasts.
|
21060154 |
2010 |
Liver neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1.
|
21112564 |
2010 |
Liver neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
Human inhibitor of growth 1 inhibits hepatoma cell growth and influences p53 stability in a variant-dependent manner.
|
19085961 |
2009 |
Liver neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
The expression of p27, p21 and p53 was assessed in well and poorly-differentiated liver tumors.
|
19672859 |
2009 |
Liver neoplasms
|
0.700 |
GeneticVariation
|
group |
LHGDN |
Sporadic childhood hepatoblastomas show activation of beta-catenin, mismatch repair defects and p53 mutations.
|
17962810 |
2008 |
Liver neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
Enhancement of p53 gene transfer efficiency in hepatic tumor mediated by transferrin receptor through trans-arterial delivery.
|
18347429 |
2008 |